Published in J Exp Med on December 01, 1997
Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J Exp Med (2002) 2.32
A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect Immun (1998) 2.02
Susceptibility to secondary Francisella tularensis live vaccine strain infection in B-cell-deficient mice is associated with neutrophilia but not with defects in specific T-cell-mediated immunity. Infect Immun (2001) 1.91
Role of antibodies in immunity to Bordetella infections. Infect Immun (2003) 1.71
Importance of B cells, but not specific antibodies, in primary and secondary protective immunity to the intracellular bacterium Francisella tularensis live vaccine strain. Infect Immun (1999) 1.70
Fasciola hepatica suppresses a protective Th1 response against Bordetella pertussis. Infect Immun (1999) 1.69
Igh-6(-/-) (B-cell-deficient) mice fail to mount solid acquired resistance to oral challenge with virulent Salmonella enterica serovar typhimurium and show impaired Th1 T-cell responses to Salmonella antigens. Infect Immun (2000) 1.67
Protective immunity to Bordetella pertussis requires both B cells and CD4(+) T cells for key functions other than specific antibody production. J Exp Med (2000) 1.55
Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine. PLoS Pathog (2013) 1.54
A role for TLR4 in Clostridium difficile infection and the recognition of surface layer proteins. PLoS Pathog (2011) 1.39
Pertussis toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis. J Clin Invest (2005) 1.32
Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines. Infect Immun (1999) 1.25
The O antigen enables Bordetella parapertussis to avoid Bordetella pertussis-induced immunity. Infect Immun (2007) 1.09
Suppression of serum antibody responses by pertussis toxin after respiratory tract colonization by Bordetella pertussis and identification of an immunodominant lipoprotein. Infect Immun (2004) 1.09
Bordetella pertussis expresses a functional type III secretion system that subverts protective innate and adaptive immune responses. Infect Immun (2008) 1.09
Host genetics of Bordetella pertussis infection in mice: significance of Toll-like receptor 4 in genetic susceptibility and pathobiology. Infect Immun (2006) 1.02
Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect Immun (1999) 0.99
Maternal immunity provides protection against pertussis in newborn piglets. Infect Immun (2006) 0.98
A regulatory role for interleukin 4 in differential inflammatory responses in the lung following infection of mice primed with Th1- or Th2-inducing pertussis vaccines. Infect Immun (2000) 0.94
O antigen allows B. parapertussis to evade B. pertussis vaccine-induced immunity by blocking binding and functions of cross-reactive antibodies. PLoS One (2009) 0.90
gammadelta T cells regulate the early inflammatory response to bordetella pertussis infection in the murine respiratory tract. Infect Immun (2006) 0.90
Genetic control of Bordetella pertussis infection: identification of susceptibility loci using recombinant congenic strains of mice. Infect Immun (2005) 0.90
Whole-cell but not acellular pertussis vaccines induce convulsive activity in mice: evidence of a role for toxin-induced interleukin-1beta in a new murine model for analysis of neuronal side effects of vaccination. Infect Immun (2001) 0.90
Effect of different forms of adenylate cyclase toxin of Bordetella pertussis on protection afforded by an acellular pertussis vaccine in a murine model. Infect Immun (2006) 0.90
IL-10 induction by Bordetella parapertussis limits a protective IFN-gamma response. J Immunol (2009) 0.89
Interleukin-1 receptor signaling is required to overcome the effects of pertussis toxin and for efficient infection- or vaccination-induced immunity against Bordetella pertussis. Infect Immun (2010) 0.89
Substantial gaps in knowledge of Bordetella pertussis antibody and T cell epitopes relevant for natural immunity and vaccine efficacy. Hum Immunol (2014) 0.88
Biologic functions of the IFN-gamma receptors. Allergy (1999) 0.87
Lung response to Bordetella pertussis infection in mice identified by gene-expression profiling. Immunogenetics (2007) 0.87
T- and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis. PLoS One (2010) 0.87
Neonatal antibody responses are attenuated by interferon-γ produced by NK and T cells during RSV infection. Proc Natl Acad Sci U S A (2013) 0.86
B-cell-deficient mice show an exacerbated inflammatory response in a model of Chlamydophila abortus infection. Infect Immun (2002) 0.86
Monocyte-derived interleukin-10 depresses the Bordetella pertussis- specific gamma interferon response in vaccinated infants. Clin Vaccine Immunol (2009) 0.86
A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice. Clin Vaccine Immunol (2009) 0.84
Quantitative priming with inactivated pertussis toxoid vaccine in the aerosol challenge model. Infect Immun (2002) 0.84
Loss of multi-epitope specificity in memory CD4(+) T cell responses to B. pertussis with age. PLoS One (2013) 0.83
Protective effects of pertussis immunoglobulin (P-IGIV) in the aerosol challenge model. Clin Diagn Lab Immunol (1999) 0.83
Roads to the development of improved pertussis vaccines paved by immunology. Pathog Dis (2015) 0.81
T-cell immune response assessment as a complement to serology and intranasal protection assays in determining the protective immunity induced by acellular pertussis vaccines in mice. Clin Diagn Lab Immunol (2003) 0.81
Acellular pertussis vaccine protects against exacerbation of allergic asthma due to Bordetella pertussis in a murine model. Clin Diagn Lab Immunol (2005) 0.81
Comparative gene expression profiling in two congenic mouse strains following Bordetella pertussis infection. BMC Microbiol (2007) 0.81
Decreased leukocyte accumulation and delayed Bordetella pertussis clearance in IL-6-/- mice. J Immunol (2011) 0.81
Waning and aging of cellular immunity to Bordetella pertussis. Pathog Dis (2015) 0.81
Protective Role of Passively Transferred Maternal Cytokines against Bordetella pertussis Infection in Newborn Piglets. Infect Immun (2017) 0.77
Review of the neutrophil response to Bordetella pertussis infection. Pathog Dis (2015) 0.77
A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model. Clin Vaccine Immunol (2010) 0.77
c-di-GMP enhances protective innate immunity in a murine model of pertussis. PLoS One (2014) 0.76
A critical role for the TLR signaling adapter Mal in alveolar macrophage-mediated protection against Bordetella pertussis. Mucosal Immunol (2014) 0.76
The route less taken: pulmonary models of enteric Gram-negative infection. Pathog Dis (2013) 0.75
Immune responses to pertussis antigens in infants and toddlers after immunization with multicomponent acellular pertussis vaccine. Clin Vaccine Immunol (2014) 0.75
CD71(+) erythroid suppressor cells impair adaptive immunity against Bordetella pertussis. Sci Rep (2017) 0.75
An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med (1993) 18.56
Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med (1993) 17.01
A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature (1991) 13.19
Immune response in mice that lack the interferon-gamma receptor. Science (1993) 12.15
Generation and analysis of interleukin-4 deficient mice. Science (1991) 8.80
A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med (1996) 5.07
A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N Engl J Med (1996) 4.86
Bordetella holmesii sp. nov., a new gram-negative species associated with septicemia. J Clin Microbiol (1995) 3.63
Different roles of alpha beta and gamma delta T cells in immunity against an intracellular bacterial pathogen. Nature (1993) 3.47
Invasion of HeLa 229 cells by virulent Bordetella pertussis. Infect Immun (1989) 3.27
Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect Immun (1993) 3.04
Integrin-mediated localization of Bordetella pertussis within macrophages: role in pulmonary colonization. J Exp Med (1991) 2.79
Bordetella pertussis infection in mice: correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin with mouse protectivity in an intracerebral or aerosol challenge system. Infect Immun (1984) 2.72
Cloning and sequencing of a Bordetella pertussis serum resistance locus. Infect Immun (1994) 2.39
Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity. Infect Immun (1993) 2.36
Aerosol infection of mice with Bordetella pertussis. Infect Immun (1980) 2.31
Bordetella pertussis respiratory infection in children is associated with preferential activation of type 1 T helper cells. J Infect Dis (1997) 1.92
Macrophage behaviour during the complaisant phase of murine pertussis. Immunology (1969) 1.85
Bacteremia caused by a novel Bordetella species, "B. hinzii". J Clin Microbiol (1994) 1.63
Detection of Bordetella pertussis associated with the alveolar macrophages of children with human immunodeficiency virus infection. Infect Immun (1991) 1.62
Interleukin-12 is produced by macrophages in response to live or killed Bordetella pertussis and enhances the efficacy of an acellular pertussis vaccine by promoting induction of Th1 cells. Infect Immun (1996) 1.61
Placebo-controlled trial of two acellular pertussis vaccines in Sweden--protective efficacy and adverse events. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet (1988) 1.55
Generation of nitric oxide and induction of major histocompatibility complex class II antigen in macrophages from mice lacking the interferon gamma receptor. Proc Natl Acad Sci U S A (1993) 1.45
Modulation of Bordetella pertussis infection with monoclonal antibodies to pertussis toxin. J Infect Dis (1991) 1.32
Bordetella bronchiseptica pneumonia and bacteremia following bone marrow transplantation. J Clin Microbiol (1992) 1.24
Analysis of protective and nonprotective monoclonal antibodies specific for Bordetella pertussis lipooligosaccharide. Infect Immun (1994) 1.12
Bacterial and protozoal infections in genetically disrupted mice. Curr Opin Immunol (1994) 1.09
Epithelial autotoxicity of nitric oxide: role in the respiratory cytopathology of pertussis. Proc Natl Acad Sci U S A (1994) 1.09
Bordetella pertussis-specific Th1/Th2 cells generated following respiratory infection or immunization with an acellular vaccine: comparison of the T cell cytokine profiles in infants and mice. Dev Biol Stand (1997) 1.05
Role of Th1 and Th2 cells in bacterial infections. Chem Immunol (1996) 1.00
Effects of recombinant human gamma interferon on intracellular survival of Bordetella pertussis in human phagocytic cells. FEMS Immunol Med Microbiol (1994) 0.98
The adenylate cyclase toxin contributes to the survival of Bordetella pertussis within human macrophages. Microb Pathog (1993) 0.96
IFN-gamma receptor-deficient mice are hypersensitive to the anti-CD3-induced cytokine release syndrome and thymocyte apoptosis. Protective role of endogenous nitric oxide. J Immunol (1995) 0.91
In vitro and in vivo induction of nitric oxide by murine macrophages stimulated with Bordetella pertussis. FEMS Immunol Med Microbiol (1996) 0.88
Unexpected isolation of Bordetella pertussis from a blood culture. J Clin Microbiol (1994) 0.81
Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. Lancet (2011) 10.73
floricaula: a homeotic gene required for flower development in antirrhinum majus. Cell (1990) 6.52
Analysis of 1.9 Mb of contiguous sequence from chromosome 4 of Arabidopsis thaliana. Nature (1998) 5.91
Differential localization of Rho GTPases in live cells: regulation by hypervariable regions and RhoGDI binding. J Cell Biol (2001) 5.05
Sequence and analysis of chromosome 4 of the plant Arabidopsis thaliana. Nature (1999) 5.03
FCA, a gene controlling flowering time in Arabidopsis, encodes a protein containing RNA-binding domains. Cell (1997) 4.79
Effects of a decision support system on the diagnostic accuracy of users: a preliminary report. J Am Med Inform Assoc (1997) 4.61
Multiple independent defective suppressor-mutator transposon insertions in Arabidopsis: a tool for functional genomics. Plant Cell (1999) 4.57
Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J (1987) 4.56
Genetic definition and sequence analysis of Arabidopsis centromeres. Science (1999) 4.20
Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature (1985) 3.97
Biochemical characterization of human collagenase-3. J Biol Chem (1996) 3.52
Stromelysin, a connective tissue-degrading metalloendopeptidase secreted by stimulated rabbit synovial fibroblasts in parallel with collagenase. Biosynthesis, isolation, characterization, and substrates. J Biol Chem (1985) 3.51
Comparison of human stromelysin and collagenase by cloning and sequence analysis. Biochem J (1986) 3.31
TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett (1998) 3.04
Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J Biol Chem (1996) 3.00
Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem (2001) 2.91
A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett (1992) 2.88
The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem (1998) 2.71
Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem (1997) 2.63
Conservation of microstructure between a sequenced region of the genome of rice and multiple segments of the genome of Arabidopsis thaliana. Genome Res (2001) 2.56
Molecular characterization and regulation of the rhizosphere-expressed genes rhiABCR that can influence nodulation by Rhizobium leguminosarum biovar viciae. J Bacteriol (1992) 2.55
Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci U S A (1991) 2.53
The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3. J Biol Chem (1996) 2.45
Airborne spread of measles in a suburban elementary school. Am J Epidemiol (1978) 2.37
Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity. Infect Immun (1993) 2.36
Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol (2000) 2.33
Evidence that latent collagenases are enzyme-inhibitor complexes. Biochem J (1977) 2.32
Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest Ophthalmol Vis Sci (1997) 2.28
Semliki Forest virus expression system: production of conditionally infectious recombinant particles. Biotechnology (N Y) (1993) 2.20
Purification and characterization of a rabbit bone metalloproteinase that degrades proteoglycan and other connective-tissue components. Biochem J (1983) 2.17
Sequence and analysis of chromosome 5 of the plant Arabidopsis thaliana. Nature (2000) 2.16
Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen (2000) 2.15
Identification and enzymatic characterization of two diverging murine counterparts of human interstitial collagenase (MMP-1) expressed at sites of embryo implantation. J Biol Chem (2000) 2.12
Purification of rabbit bone inhibitor of collagenase. Biochem J (1981) 2.12
Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine. Lancet (1991) 2.10
The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J Biol Chem (1997) 2.09
Relationship between x-ray exposure and malignant transformation in C3H 10T1/2 cells. Proc Natl Acad Sci U S A (1980) 2.08
British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Med (2012) 2.05
The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett (2000) 2.03
Long-term ecosystem stress: the effects of years of experimental acidification on a small lake. Science (1985) 2.03
Degradation of cartilage aggrecan by collagenase-3 (MMP-13). FEBS Lett (1996) 1.97
Human dendritic cells as targets of dengue virus infection. J Investig Dermatol Symp Proc (2001) 1.96
Bordetella pertussis respiratory infection in children is associated with preferential activation of type 1 T helper cells. J Infect Dis (1997) 1.92
Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. Hepatology (1996) 1.91
ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun (2000) 1.90
Biosynthesis of tissue inhibitor of metalloproteinases by human fibroblasts in culture. Stimulation by 12-O-tetradecanoylphorbol 13-acetate and interleukin 1 in parallel with collagenase. J Biol Chem (1985) 1.86
The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. J Biol Chem (1992) 1.85
The helping hand of collagenase-3 (MMP-13): 2.7 A crystal structure of its C-terminal haemopexin-like domain. J Mol Biol (1996) 1.82
The tissue metalloproteinase family and the inhibitor TIMP: a study using cDNAs and recombinant proteins. Ann Rheum Dis (1990) 1.80
Recent trends in HIV and other STIs in the United Kingdom: data to the end of 2002. Sex Transm Infect (2004) 1.79
Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology (1998) 1.75
Immunolocalization of tissue inhibitor of metalloproteinases (TIMP) in human cells. Characterization and use of a specific antiserum. J Cell Sci (1985) 1.73
Missed opportunities for diagnosing primary HIV infection. Sex Transm Infect (2007) 1.72
The interaction of purified rabbit bone collagenase with purified rabbit bone metalloproteinase inhibitor. Biochem J (1983) 1.72
Accelerated apoptosis in the Timp-3-deficient mammary gland. J Clin Invest (2001) 1.71
The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J Biol Chem (1995) 1.70
Fasciola hepatica suppresses a protective Th1 response against Bordetella pertussis. Infect Immun (1999) 1.69
Partial purification of collagenase and gelatinase from human polymorphonuclear leucocytes. Analysis of their actions on soluble and insoluble collagens. Biochem J (1982) 1.66
Implications for HIV testing policy derived from combining data on voluntary confidential testing with viral sequences and serological analyses. Sex Transm Infect (2008) 1.66
Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)-seropositive persons infected with diverse HIV-1 subtypes. J Clin Microbiol (2006) 1.64
The latent collagenase and gelatinase of human polymorphonuclear neutrophil leucocytes. Biochem J (1980) 1.64
Metalloproteinases from rabbit bone culture medium degrade types IV and V collagens, laminin and fibronectin. Biochem J (1981) 1.62
Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1. Implications for regulation of matrix degradation in liver. J Clin Invest (1992) 1.62
Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer (1999) 1.61
Interleukin-12 is produced by macrophages in response to live or killed Bordetella pertussis and enhances the efficacy of an acellular pertussis vaccine by promoting induction of Th1 cells. Infect Immun (1996) 1.61
Adults with late diagnosed PKU and severe challenging behaviour: a randomised placebo-controlled trial of a phenylalanine-restricted diet. J Neurol Neurosurg Psychiatry (2009) 1.60
The National Cancer Data Base report on prostate cancer. Cancer (1994) 1.60
The detection and characterisation of collagenase inhibitors from rabbit tissues in culture. Biochim Biophys Acta (1977) 1.57
Direct anti-inflammatory effect of a bacterial virulence factor: IL-10-dependent suppression of IL-12 production by filamentous hemagglutinin from Bordetella pertussis. Eur J Immunol (2000) 1.56
Purification and characterization of a bone metalloproteinase that degrades gelatin and types IV and V collagen. Biochim Biophys Acta (1985) 1.56
Cleavage of cartilage proteoglycan between G1 and G2 domains by stromelysins. J Biol Chem (1991) 1.55
Metalloproteinase-mediated regulation of L-selectin levels on leucocytes. J Biol Chem (1996) 1.55
Collagenase is a component of the specific granules of human neutrophil leucocytes. Biochem J (1977) 1.55
An inhibitor of collagenase from human amniotic fluid. Purification, characterization and action on metalloproteinases. Biochem J (1981) 1.52
A cross-site vascular radiology on-call service: the Manchester experience. Clin Radiol (2005) 1.51
Characterization of a specific antiserum to rabbit stromelysin and demonstration of the synthesis of collagenase and stromelysin by stimulated rabbit articular chondrocytes. Coll Relat Res (1986) 1.50
The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases. Trends Biotechnol (1992) 1.50
Fibroblast and neutrophil collagenases cleave at two sites in the cartilage aggrecan interglobular domain. Biochem J (1993) 1.49
Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine (2001) 1.49
Matrix metalloproteinases MMP2 and MMP9 are produced in early stages of kidney morphogenesis but only MMP9 is required for renal organogenesis in vitro. J Cell Biol (1997) 1.48
Trauma related symptoms in British soldiers 36 months following a tour in the former Yugoslavia. J R Army Med Corps (1999) 1.46
Fibrillin degradation by matrix metalloproteinases: implications for connective tissue remodelling. Biochem J (1999) 1.45
OAS1: a multiple sclerosis susceptibility gene that influences disease severity. Neurology (2010) 1.45
Assessment of postoperative pain management: patient satisfaction and perceived helpfulness. Clin J Pain (1997) 1.45
Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7-1, B7-2 and CD28. Int Immunol (1998) 1.44
Shedding of c-Met is regulated by crosstalk between a G-protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase. J Cell Sci (2001) 1.42
Interleukin-8 overexpression is present in pyoderma gangrenosum ulcers and leads to ulcer formation in human skin xenografts. Lab Invest (2000) 1.42
Intermolecular autolytic cleavage can contribute to the activation of progelatinase A by cell membranes. J Biol Chem (1995) 1.41
Binding of gelatinases A and B to type-I collagen and other matrix components. Biochem J (1995) 1.41
Volume of distribution and fractional clearance of urea in amputees on continuous ambulatory peritoneal dialysis. Perit Dial Int (1994) 1.40
Gelatinase A not alpha-secretase? Nature (1994) 1.40